Skip to main content
TCRT
NASDAQ Life Sciences

Alaunos 10-Q: $350M PIPE Erases Going-Concern Doubt, But 381M Conversion Shares Loom

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$1.52
Mkt Cap
$7.238M
52W Low
$0.719
52W High
$4.5
52W Position info
111% above low
Off High info
66% below high
Rel. Volume
Market data snapshot near publication time

TCRT has more than doubled off its 52-week low of $0.719.

Summary

Alaunos filed its first 10-Q since the Velaris merger and $350 million PIPE, showing going-concern doubt resolved but roughly 381.4 million preferred conversion shares still needing stockholder approval, with cash-settlement rights if that vote fails.


Key Events · Earnings and Guidance · TCRT

  • First Post-Merger Quarterly Report

    September 30, 2026 balance sheet shows $0.62 million of cash, a $927.4 million accumulated deficit and a $2.7 million net loss for the nine months; it precedes the October 13 Velaris acquisition and October 14 PIPE.

  • Going-Concern Doubt Cleared

    Management concluded the $350.0 million gross PIPE proceeds fund planned operations for at least one year from the issuance date, alleviating the substantial doubt previously raised.

  • 381.4M Conversion Shares Need Approval

    Series B and Series C preferred convert into roughly 381.4 million common shares against 4.2 million outstanding as of November 16; without stockholder approval, holders can demand cash settlement beginning six months after issuance, and only 6,268 Series C shares (~$9.0 million) are waived.

  • Paragon $200M Equity Trigger

    Paragon may terminate the licenses, with rights reverting, if stockholders' equity does not exceed $200 million at the end of the second full fiscal quarter after the October 13 closing.


Analysis · TCRT · Life Sciences

This is the first full look at Alaunos after the Velaris asset acquisition and the $350.0 million PIPE closed in mid-October. The September 30 balance sheet still shows the old shell: $0.62 million of cash, a $927.4 million accumulated deficit and a $2.7 million nine-month net loss. Management now says the PIPE proceeds fund operations for at least a year, so the going-concern warning is gone. The catch is the structure: the Series B and Series C preferred convert into roughly 381.4 million common shares, against 4.2 million shares outstanding as of November 16, and if stockholders do not approve the conversion, holders can demand cash settlement beginning six months after issuance. Only 6,268 Series C shares, about $9.0 million, are covered by Fairmount's waiver, so a failed vote could force a cash payment that exceeds the company's resources. The proxy vote on that conversion is the event that decides whether this is a funded biotech or a cash-settlement problem.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TCRT was trading at $1.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $0.72 to $4.50. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TCRT - Latest Insights

TCRT
Nov 13, 2026, 5:30 PM EST
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $1.56
Real-time Price: $1.52 info
Change: -$0.040 (-3%) info
Market Cap: $7.238M info
TCRT
Nov 12, 2026, 7:49 PM EST
Filing Type: S-3
Importance Score:
7
Price at Filing: $1.60
Real-time Price: $1.52 info
Change: -$0.0799 (-5%) info
Market Cap: $7.238M info
TCRT
Oct 23, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.45
Real-time Price: $1.52 info
Change: -$0.930 (-38%) info
Market Cap: $7.238M info
TCRT
Oct 21, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.15
Real-time Price: $1.52 info
Change: -$1.63 (-52%) info
Market Cap: $7.238M info
TCRT
Oct 15, 2026, 7:55 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $2.88
Real-time Price: $1.52 info
Change: -$1.36 (-47%) info
Market Cap: $7.238M info